Alkermes Plc
$ 49.17
1.65%
07 Aug - close price
- Market Cap 8,248,920,000 USD
- Current Price $ 49.17
- High / Low $ 49.90 / 48.67
- Stock P/E 126.08
- Book Value 10.79
- EPS 0.39
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.04 %
- 52 Week High 55.67
- 52 Week Low 25.17
About
Alkermes plc, a biopharmaceutical company, researches, develops and markets pharmaceutical products to address the unmet medical needs of patients in various therapeutic areas in the United States, Ireland and internationally. The company is headquartered in Dublin, Ireland.
Analyst Target Price
$56.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-28 | 2026-05-05 | 2026-02-25 | 2025-10-28 | 2025-07-29 | 2025-05-01 | 2025-02-12 | 2024-10-24 | 2024-07-24 | 2024-05-01 | 2024-02-15 | 2023-10-25 |
| Reported EPS | 0.52 | 0.38 | 0.29 | 0.65 | 0.68 | 0.29 | 1.05 | 0.73 | 0.7 | 0.43 | 0.22 | 0.64 |
| Estimated EPS | -0.04 | -0.04 | 0.41 | 0.39 | 0.4 | 0.24 | 0.76 | 0.71 | 0.71 | 0.58 | 0.51 | 0.43 |
| Surprise | 0.56 | 0.42 | -0.12 | 0.26 | 0.28 | 0.05 | 0.29 | 0.02 | -0.01 | -0.15 | -0.29 | 0.21 |
| Surprise Percentage | 1400% | 1050% | -29.2683% | 66.6667% | 70% | 20.8333% | 38.1579% | 2.8169% | -1.4085% | -25.8621% | -56.8627% | 48.8372% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALKS
2026-08-04 00:39:55
This article announces that Alkermes plc (ALKS) filed a Form 4 on August 3rd. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders (officers, directors, or beneficial owners of more than 10% of a class of the company's equity securities) to report changes in their ownership of the company's stock. The article is a brief notification from Investing.com and provides no further details about the specific contents of the filing.
2026-08-03 20:39:55
An Alkermes plc insider, Craig Hopkinson, plans to sell 9,000 ordinary shares on August 3, 2026, valued at approximately $437,220. These shares originate from employee stock option exercises and vesting of performance and restricted stock awards. The filing also reveals Hopkinson's previous monthly sales of 9,000 shares each from March to July 2026.
2026-08-03 20:39:55
Alkermes plc insider David Gaffin plans to sell Alkermes common stock through Merrill Lynch, with a total market value of $98,811.72. These sales relate to restricted stock unit and performance share unit awards that vested between 2014 and 2016. Gaffin has also reported monthly open-market sales from April to July 2026, generating proceeds ranging from $70,315.38 to $109,897.02.
2026-08-02 11:19:41
Alkermes plc experienced a 7.4% stock drop after reporting a sharp decline in Q2 2026 net income to US$0.501 million, despite a revenue increase to US$496.01 million. The company also filed a US$311.11 million equity shelf registration, signaling a shift from capital returns to potential financing and compensation needs, raising concerns about profitability and capital allocation for investors.
2026-08-01 08:39:55
Alkermes plc (ALKS) experienced a 7.4% stock drop after reporting a sharp decline in Q2 2026 net income to US$0.501 million from US$87.1 million, despite increased revenue. The company also filed a US$311.11 million shelf registration for 5,900,000 ordinary shares, indicating a shift from capital returns to equity issuance for compensation and potential financing, further complicating its investment narrative focused on profitability and capital allocation.
2026-07-30 11:41:09
H.C. Wainwright reiterated a Neutral rating on Alkermes (NASDAQ:ALKS) shares following strong second-quarter results, where proprietary product sales rose 34% year-over-year, exceeding consensus estimates. Despite impressive sales for products like Vivitrol and the Aristada family, and significant growth in Lybalvi prescriptions and Lumryz sales, the stock is considered overvalued by InvestingPro. The company largely maintained its full-year guidance and is focused on its orexin programs for long-term growth, while also managing increasing costs.
